The story so far · 2 days, November 15 to 16, 2026
FDA rejects China's lung cancer drug ivonescimab
One Turn followed this story across 2 editions, from Washington, United States on November 15, 2026. Newest first.
Akeso is a Hong Kong-listed Chinese biotech company.
Open the latest on the 3D globe →
Day by day
Nov 15 US FDA rejects China lung cancer drug Nov 16 FDA rejects China's lung cancer drug ivonescimab
Every installment
Monday, November 16, 2026 · Day 2 · Health · Hong Kong · China
The US FDA rejected Akeso's cancer drug ivonescimab. Akeso shares fell as much as 31.8% in Hong Kong. The drug had become a symbol of China's rise in drug development.
Why it matters: The decision is a setback for Chinese drugmakers seeking US approval.
Sources: South China Morning Post , The Straits Times · See it on the globe
Sunday, November 15, 2026 · Day 1 · Health · Washington, United States · United States of America
The FDA rejected ivonescimab, a closely watched lung cancer drug from China. It had become a symbol of China's rise in drug development.
Why it matters: It affects Chinese drugmakers' hopes in the US market.
Sources: The Straits Times · See it on the globe
Where
More running stories →